Mobile

A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorecta...

Update Il y a 4 ans
Reference: EUCTR2008-004706-14

A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorectal liver metastases

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the effect of the monoclonal AB adecatumumab alone or sequentially to FOLFOX on 1 year disease-free survival (DFS) rates in colorectal cancer patients with complete (R0) resection of liver metastases

Inclusion criteria

  • R0 resected liver metastases from colorectal cancer

Links